Genetic therapies for the fetus

Clinical Obstetrics and Gynecology

Volumn 45, Issue 3, 2002, Pages 684-696

  Flake, Alan W ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA;

BLOOD DISEASE; CELL PROLIFERATION; CELL SURVIVAL; COMBINED IMMUNODEFICIENCY; FETUS; FETUS CELL; GENE MUTATION; GENE THERAPY; GENE TRANSFER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYSOSOME STORAGE DISEASE; MUSCULAR DYSTROPHY; PRENATAL CARE; PRENATAL DIAGNOSIS; REVIEW; SAFETY; TREATMENT INDICATION;

ANIMALS; FETAL DISEASES; FETUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; SEVERE COMBINED IMMUNODEFICIENCY; WISKOTT-ALDRICH SYNDROME;

EID: 0036408320     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200209000-00012     Document Type: Review

References (78)

1. Flake AW, Zanjani ED. In utero hematopoietic stem cell transplantation: Ontogenic opportunities and biologic barriers. Blood. 1999;94:2179-2191.
2. Blackman M, Kappler J, Marrack P. The role of the T-cell receptor in positive and negative selection of developing T-cells. Science. 1990;248:1335-1342.
3. Schwartz R. Acquisition of immunologic self tolerance. Cell. 1989;57:1073-1081.
4. Sha WC, Nelson CA, Newberry RD, et al. Positive and negative selection of an antigen receptor on T-cells in transgenic mice. Nature. 1988;336:73-76.
5. Flake AW, Harrison MR, Adzick NS, Zanjani ED. Transplantation of fetal hematopoietic stem cells in utero: The creation of hematopoietic chimeras. Science. 1986;233:776-778.
6. Harrison DE, Astle CM. Short- and long-term multilineage repopulating hematopoietic stem cells in late fetal and newborn mice: Models for human umbilical cord blood transplantation. Blood. 1997;90:174-181.
7. Wolf NS, Bertoncello I, Jiang D, Priestley G. Developmental hematopoiesis from prenatal to young-adult life in the mouse model. Exp Hematol. 1995;23:142-146.
8. Flake A, Zanjani E. Cellular therapy. Obstet Gynecol Clin North Am. 1997;24:159-177.
9. Shaaban AF, Kim HB, Milner R, Flake AW. A kinetic model for homing and migration of prenatally transplanted marrow. Blood. 1999;94:3251-3257.
10. Archer DR, Turner CW, Yeager AM, Fleming WH. Sustained multilineage engraftment of allogeneic hematopoietic stem cells in NOD/SCID mice after in utero transplantation. Blood. 1997;90:3222-3229.
11. Blazar BR, Taylor PA, Vallera DA. In utero transfer of adult bone marrow cells into recipients with severe combined immunodeficiency disorder yields lymphoid progeny with T- and B-cell functional capabilities. Blood. 1995;86:4353-4366.
12. Blazer BR, Taylor PA, McElmurry R, et al. Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via in utero or postnatal transfer. Blood. 1998;92:3949-3959.
13. Fleischman R, Mintz B. Prevention of genetic anemias in mice by microinjection of normal hematopoietic cells into the fetal placenta. Proc Natl Acad Sci USA. 1979;76:5736-5740.
14. Fleischman RA, Custer RP, Mintz B. Totipotent hematopoietic stem cells: Normal self-renewal and differentiation after transplantation between mouse fetuses. Cell. 1982;30:351-359.
15. Flake A, Roncarolo M-G, Puck J, et al. Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow. N Engl J Med. 1996;335:1806-1810.
16. Wengler G, Lanfranchi A, Frusca T, et al. In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDX1). Lancet. 1996;348:1484-1487.
17. Hedrick MH, Rice HE, MacGillivray TE, et al. Hematopoietic chimerism achieved by in utero hematopoietic stem cell injection does not induce donor-specific tolerance for renal allografts in sheep. Transplantation. 1994;58:110-111.
18. Kim HB, Shaaban AF, Yang EY, et al. Microchimerism and tolerance after in utero bone marrow transplantation in mice. J Surg Res. 1998;77:1-5.
19. Guidos CJ, Danska JS, Fatman CJ, et al. T cell receptor-mediated negative selection of autoreactive T lymphocyte precursors occurs after commitment to the CD4 or CD8 lineages. J Exp Med. 1990;172:835-845.
20. Weissman IL. Developmental switches in the immune system. Cell. 1994;76:207-218.
21. Hayashi S, Peranteau WH, Shaaban AF, Flake AW. Complete allogeneic hematopoietic chimerism achieved by a combined strategy of in utero hematopoietic stem cell transplantation and postnatal donor lymphocyte infusion. Blood (in press).
22. Kim HB, Shaaban AF, Milner R, et al. In utero bone marrow transplantation induces tolerance by a combination of clonal deletion and anergy. J Pediatr Surg. 1999;34:726-730.
23. Shaaban AF, Milner R, Kim HB, et al. Donor T-cell education in stable high-level hematopoietic chimeric mice after prenatal MHC-disparate hematopoietic stem cell transplantation [abstract 252]. Transplantation. 1999;67:S605.
24. Shaaban AF, Milner R, Kim HB, Flake AW. High-level allogeneic hematopoietic chimerism after prenatal stem cell transplantation requires negative selection of donor thymocytes mediated by host antigen presentation cells. Exp Hematol. 1999;27(Suppl 1):347.
25. Carrier E, Gilpin E, Lee TH, et al. Microchimerism does not induce tolerance after in utero transplantation and may lead to the development of alloreactivity. J Lab Clin Med. 2000;136:224-235.
26. Crombleholme TM, Harrison MR, Zanjani ED. In utero transplantation of hematopoietic stem cells in sheep: The role of T cells in engraftment and graft-versus-host disease. J Pediatr Surg. 1990;25:885-892.
27. Muench MO, Rae J, Barcena A, et al. Transplantation of a fetus with paternal Thy1(+)CD34(+)cells for chronic granulomatous disease. Bone Marrow Transplant. 2001;27:355-364.
28. Heeg K, Wagner H. Induction of peripheral tolerance to class I major histocompatibility complex (MHC) alloantigens in adult mice: Transfused class I MHC-incompatible splenocytes veto clonal responses of antigen-reactive Lyt-2+ T cells. J Exp Med. 1990;172:719-728.
29. Thomas JM, Verbanac KM, Carver FM, et al. Veto cells in transplantation tolerance. Clin Transplant. 1994;8:195-203.
30. Kumar V, George T, Yu YYL, et al. Role of murine NK cells and their receptors in hybrid resistance. Curr Opin Immunol. 1997;9:52-56.
31. Shevach EM. Regulatory T cells in autoimmmunity. Annu Rev Immunol. 2000;18:423-449.
32. Flake AW, Zanjani ED. In utero hematopoietic stem cell transplantation. A status report. JAMA. 1997;278:932-937.
33. Jones DR, Bui TH, Anderson EM, et al. In utero haematopoietic stem cell transplantation: Current perspectives and future potential. Bone Marrow Transplant. 1996;18:831-837.
34. Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency: Genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr. 1997;130:378-387.
35. Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340:508-516.
36. Flake AW, Zanjani ED. Treatment of severe combined immunodeficiency [letter to the editor]. N Engl J Med. 1999;341:291.
37. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346:1185-1193.
38. Gallego MD, Santamaría M, Peña J, Molina IJ. Defective actin reorganization and polymerization of Wiskott-Aldrich T cells in response to CD3-mediated stimulation. Blood. 1997;90:3089-3097.
39. Prchal JT, Carroll AJ, Prchal JF, et al. Wiskott-Aldrich syndrome: Cellular impairments and their implication for carrier detection. Blood. 1980;56:1048-1054.
40. Puck JM, Siminovitch KA, Poncz M, et al. Atypical presentation of Wiskott-Aldrich syndrome: Diagnosis in two unrelated males based on studies of maternal T cell X chromosome inactivation. Blood. 1990;75:2369-2374.
41. Wengler G, Gorlin JB, Williamson JM, et al. Nonrandom inactivation of the X chromosome in early lineage hematopoietic cells in carriers of Wiskott-Aldrich syndrome. Blood. 1995;85:2471-2477.
42. Puck J, Krauss C, Puck S, et al. Prenatal test for X-linked severe combined immunodeficiency by analysis of maternal X-chromosome inactivation and linkage analysis. N Engl J Med. 1990;322:1063-1066.
43. Filipovich AH, Shapiro RS, Ramsay NK, et al. Unrelated donor bone marrow transplantation for correction of lethal congenital immunodeficiencies. Blood. 1992;80:270-276.
44. Mullen CA, Anderson KD, Blaese RM. Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: Long-term follow-up of 62 cases. Blood. 1993;82:2961-2966.
45. Kvittengen EA, Rootwelt H, Brandtzaeg P, et al. Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect. J Clin Invest. 1993;91:1816-1823.
46. Hirschhorn R, Yang DR, Puck JM, et al. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat Genet. 1996;13:290-296.
47. D'Andrea AD, Grompe M. Molecular biology of Fanconi anemia: Implications for diagnosis and therapy. Blood. 1997;90:1725-1736.
48. Ellis NA, Lennon DJ, Proytcheva M, et al. Somatic intragenic recombination within the mutated locus BLM can correct the high sister-chromatid exchange phenotype of Bloom syndrome cells. Am J Hum Genet. 1995;57:1019-1027.
49. Andreani M, Manna M, Lucarelli G, et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood. 1996;87:3494-3499.
50. Or R, Kapelushnik J, Naparstek E, et al. Second transplantation using allogeneic peripheral blood stem cells in a beta-thalassaemia major patient featuring stable mixed chimaerism. Br J Hematol. 1996;94:285-287.
51. Stewart FM, Zhong S, Wuu J, et al. Lymphohematopoietic engraftment in minimally myeloablated hosts. Blood. 1998;91:3681-3687.
52. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 1999;353:1755-1759.
53. Peranteau WH, Hayashi S, Hsieh M, et al. High-level allogeneic chimerism achieved by a strategy of prenatal tolerance induction and postnatal non-myeloablative bone marrow transplantation. Blood (in press).
54. Brazelton TR, Rossi FM, Keshet GI, Blau HM. From marrow to brain: Expression of neuronal phenotypes in adult mice. Science. 2000;290:1775-1779.
55. Ferrari G, Cusella-De Angelis G, Coletta M, et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science. 1998;279:1528-1530.
56. Gussoni E, Soneoka Y, Strickland CD, et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature. 1999;401:390-394.
57. Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001;105:369-377.
58. Liechty KW, MacKenzie TC, Shaaban AF, et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med. 2000;6:1282-1286.
59. Prenatal gene tranfer: Scientific, medical, and ethical issues: A report of the Recombinant DNA Advisory Committee. Hum Gene Ther. 2000;11:1211-1229.
60. Pitt BR, Schwarz MA, Pilewski JM, et al. Retrovirus-mediated gene transfer in lungs of living fetal sheep. Gene Ther. 1995;2:344-350.
61. Turkay A, Saunders T, Kurachi K. Intrauterine gene transfer: Gestational stage-specific gene delivery in mice. Gene Ther. 1999;6:1685-1694.
62. Porada CD, Tran N, Eglitis M, et al. In utero gene therapy: Transfer and long-term expression of the bacterial neo(r) gene in sheep after direct injection of retroviral vectors into preimmune fetuses. Hum Gene Ther. 1998;9:1571-1585.
63. Tran ND, Porada CD, Zhao Y, et al. In utero transfer and expression of exogenous genes in sheep. Exp Hematol. 2000;28:17-30.
64. Holzinger A, Trapnell BC, Weaver TE, et al. Intraamniotic administration of an adenoviral vector for gene transfer to fetal sheep and mouse tissues. Pediatr Res. 1995;38:844-850.
65. Larson JE, Morrow SL, Delcarpio JB, et al. Gene transfer into the fetal primate: Evidence for the secretion of transgene product. Molecular Therapy. 2000;2:631-639.
66. Larson JE, Morrow SL, Happel L, et al. Reversal of cystic fibrosis phenotype in mice by gene therapy in utero. Lancet. 1997;349:619-620.
67. McCray PB Jr, Armstrong K, Zabner J, et al. Adenoviral-mediated gene transfer to fetal pulmonary epithelia in vitro and in vivo. J Clin Invest. 1995;95:2620-2632.
68. Iwamoto HS, Trapnell BC, McConnell CJ, et al. Pulmonary inflammation associated with repeated, prenatal exposure to an E1, E3-deleted adenoviral vector in sheep. Gene Ther. 1999;6:98-106.
69. Sylvester KG, Yang EY, Cass DL, et al. Fetoscopic gene therapy for congenital lung disease. J Pediatr Surg. 1997;32:964-969.
70. Vincent MC, Trapnell BC, Baughman RP, et al. Adenovirus-mediated gene transfer to the respiratory tract of fetal sheep in utero. Hum Gene Ther. 1995;6:1019-1028.
71. Christensen G, Minamisawa S, Gruber PJ, et al. High-efficiency, long-term cardiac expression of foreign genes in living mouse embryos and neonates. Circulation. 2000;101:178-184.
72. Lipshutz GS, Flebbe-Rehwaldt L, Gaensler KM. Adenovirus-mediated gene transfer in the midgestation fetal mouse. J Surg Res. 1999;84:150-156.
73. Lipshutz GS, Flebbe-Rehwaldt L, Gaensler KM. Adenovirus-mediated gene transfer to the peritoneum and hepatic parenchyma of fetal mice in utero. Surgery. 1999;126:171-177.
74. Mitchell M, Jerebtsova M, Batshaw ML, et al. Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors. Gene Ther. 2000;7:1986-1992.
75. Lipshutz GS, Sarkar R, Flebbe-Rehwaldt L, et al. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero. Proc Natl Acad Sci USA. 1999;96:13324-13329.
76. Yang EY, Kim HB, Shaaban AF, et al. Persistent postnatal transgene expression in both muscle and liver after fetal injection of recombinant adenovirus. J Pediatr Surg. 1999;34:766-772.
77. Lipshutz GS, Gruber CA, Cao Y, et al. In utero delivery of adeno-associated viral vectors: Intraperitoneal gene transfer produces long-term expression. Mol Ther. 2001;3:284-292.
78. Schneider H, Muhle C, Marie Douar A, et al. Sustained delivery of therapeutic concentrations of human clotting factor IX: A comparison of adenoviral and AAV vectors administered in utero. J Gene Med. 2002;4:46-53.